Gritstone Poised To Dominate mRNA Market

  • Gilead Sciences and Gritstone bio have a collaboration on a vaccine platform for curing HIV. Gilead has already paid $30 million upfront and bought $35 million in stock.
  • Gritstone bio recently completed a $55 million PIPE with leading life sciences investors Frazier Life Sciences, Redmile Group, and Gilead Sciences.
  • Gritstone announced groundbreaking early-stage clinical data at ESMO 2021 from their personalized immunotherapy program GRANITE for microsatellite stable colorectal cancer; pivotal trial to start soon.
  • The company has multiple ongoing trials that are evaluating self-amplifying mRNA as next-gen vaccine technology to combat COVID-19.
  • GRTS recently dosed the first solid tumor patient in Phase 2 clinical trials studying an optimized SLATE v2 cassette of their  “Off-the-Shelf” immunotherapy

For further information, see Seeking Alpha (

Leave a Reply

Your email address will not be published. Required fields are marked *